Skip to Content

View Additional Section Content

CP3R and AJH’s Performance for Non-Small Cell Lung Cancer

SURGERY IS NOT FIRST COURSE OF TREATMENT FOR NON-SMALL CELL LUNG CANCER THAT HAS NOT SPREAD TO DISTANT ORGANS OR AREAS

Surgery is not First Course of Treatment for Non-Small Cell Lung Cancer That Has Not Spread to Distant Organs or Areas

This quality measure examines whether surgery was used within the first course of treatment for Non-Small Cell Lung Cancer that has not spread to other organs. Abington – Jefferson Health’s compliance rate of 90.9% is below the CoC standard rate of 92.7%.


CHEMOTHERAPY IN LYMPH NODE POSITIVE NON-SMALL CELL LUNG CANCER

Chemotherapy in Lymph Node Positive Non-Small Cell Lung Cancer

Chemotherapy administered within four months to day preoperatively or day of surgery to six months postoperatively, or it is considered for surgically resected cases with pathologic, lymph node positive Non-Small Cell Lung Cancer. Abington – Jefferson Health’s compliance is 100% compared to the CoC average of 92.3%.